Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics, |
RCV001253260 | SCV001428884 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-07-09 | criteria provided, single submitter | clinical testing | |
Department of Human Genetics, |
RCV001253260 | SCV005088413 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2024-07-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004601426 | SCV005097515 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-05-29 | criteria provided, single submitter | clinical testing | The c.4548delC pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of one nucleotide at nucleotide position 4548, causing a translational frameshift with a predicted alternate stop codon (p.E1518Nfs*25). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |